Other languages Inhibikase Therapeutics, Inc.

Equities

IKT

US45719W2052

Delayed Nasdaq Other stock markets 04:00:00 2024-07-02 pm EDT			5-day change	1st Jan Change
1.21 ^USD	-2.42%		-12.67%	-4.72%

Jun. 17	Inhibikase Therapeutics Completes Enrollment of the Phase 2 ?201? Trial Evaluating Risvodetinib in Untreated Parkinson?s Disease	CI
Jun. 05	Inhibikase Therapeutics, Inc. Announces Expansion to Its Therapeutic Pipeline	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Inhibikase Therapeutics Completes Enrollment of the Phase 2 ?201? Trial Evaluating Risvodetinib in Untreated Parkinson?s Disease	Jun. 17
Inhibikase Therapeutics, Inc. Announces Expansion to Its Therapeutic Pipeline	Jun. 05
Inhibikase Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15
Inhibikase Therapeutics Announces Final Pre-Ind Meeting Outcomes for Ikt-001Pro as A Treatment for Pulmonary Arterial Hypertension	May. 09
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension	Apr. 03
Inhibikase Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib At the 2024 International Conference Onzheimer's and Parkinson's Diseases and Related Neurological Disorders	Mar. 07
Inhibikase Therapeutics Announces Preliminary Outcomes of Its Pre-Nda Meeting with the Fda on the Pathway for Approval for Ikt-001Pro in Blood and Gastrointestinal Cancers	Feb. 07
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib	Jan. 29
Inhibikase Therapeutics, Inc. Provides Update on Development Programs	Dec. 19
Inhibikase Therapeutics, Inc. Granted Pre-NDA Meeting with the FDA for IkT-001Pro	Dec. 04
Inhibikase Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson?s Disease and Provides Update on Ongoing Enrollment	23-10-16
Sector Update: Health Care Stocks Advancing Late Afternoon	23-10-04
Sector Update: Health Care Stocks Lower Wednesday Afternoon	23-10-04
Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Potential Multiple System Atrophy Treatment	23-10-04
Inhibikase Therapeutics, Inc. Announces Development of Novel Formulation of Rampsvodetinib	23-08-24
Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of Ikt-001Pro	23-08-17
Inhibikase Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Top Premarket Gainers	23-06-30

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Inhibikase Therapeutics, Inc.

Equities

IKT

US45719W2052

Other languages

Filters